Urinary Sex Steroid Metabolites: Sex- and Cycle-Related Differences, Normal Ranges, and Optimal Targets

What Are Urinary Sex Steroid Metabolites?

Urinary sex steroid metabolites are the downstream breakdown products of estrogens, androgens, and progestogens that the liver processes and the kidneys excrete. Measuring them provides a window into hormone production and metabolism that serum tests cannot fully capture, because blood levels reflect circulating hormone at one moment while urine reflects cumulative metabolic output over hours.

The Core Metabolites Clinicians Track

Estrogens undergo phase-I hydroxylation at the C-2, C-4, or C-16 position of the steroid ring. This produces three families of metabolites with distinct biological activity. 2-hydroxyestrone (2-OHE1) is considered a "weaker" estrogen with anti-proliferative properties at physiologic concentrations. 16-alpha-hydroxyestrone (16-OHE1) retains significant estrogen-receptor binding affinity and promotes cell proliferation in vitro. 4-hydroxyestrone (4-OHE1) generates quinone intermediates capable of forming DNA adducts, which is the basis for concern about this pathway in breast tissue [1].

Phase-II methylation by catechol-O-methyltransferase (COMT) converts 2-OHE1 to 2-methoxyestrone (2-MeOE1). Low COMT activity or insufficient methyl donors (folate, B12, SAM-e) can shift the balance away from this protective step [2].

Androgens and Progesterone Metabolites

Beyond estrogens, the panel typically includes:

• Testosterone glucuronide and sulfate conjugates: reflect androgenic output and 5-alpha-reductase activity.
• DHEA-S (dehydroepiandrosterone sulfate): the dominant adrenal androgen, useful for assessing adrenal contribution.
• Pregnanediol-3-glucuronide (PDG): the primary urinary metabolite of progesterone, used to confirm ovulation and luteal-phase adequacy [3].
• Androsterone and etiocholanolone: 17-ketosteroid metabolites that reflect androgen turnover in both sexes.

The 2-OH/16-OH Ratio: Clinical Meaning and Evidence Base

The ratio of 2-OHE1 to 16-OHE1 has been studied as a breast-cancer risk biomarker since the early 1990s. The hypothesis is straightforward: a higher ratio indicates more flux through the anti-proliferative pathway and less through the proliferative one.

Prospective Evidence

The Nurses' Health Study II nested case-control analysis (N=712 cases, 1,399 controls) found that premenopausal women in the highest quartile of the 2-OH/16-OH ratio had a statistically significant reduction in breast-cancer risk compared with the lowest quartile (odds ratio 0.70, 95% CI 0.52 to 0.95, P<0.05) [4]. The ORDET cohort study from Italy similarly reported that women with 2-OH/16-OH ratios below 1.0 had approximately a 30% higher relative risk of breast cancer compared with those above 2.0 [5].

A 2014 meta-analysis published in Cancer Epidemiology, Biomarkers and Prevention reviewed 13 prospective studies and concluded that the relationship between the 2-OH/16-OH ratio and breast-cancer risk is modest but consistent in premenopausal women, with the association weaker or absent in postmenopausal women [6].

What "Optimal" Means in Context

"Optimal" is not the same as "normal." Most commercial labs report a reference range of 1.0 to 7.8 for the 2-OH/16-OH ratio, based on population distributions. Functional and longevity-medicine clinicians generally target 2.0 to 4.0 as the preferred zone for premenopausal women, based on the risk quartiles in the Nurses' Health Study II data [4]. Values above 6.0 can occur with high cruciferous-vegetable intake or supplemental I3C/DIM and do not appear harmful, though data beyond 8.0 are limited.

The HealthRX clinical team applies a three-tier interpretation framework for the 2-OH/16-OH ratio:

| Ratio | Interpretation | Typical Next Step | |---|---|---| | <1.5 | Suboptimal, elevated proliferative pathway | Assess diet, COMT genotype, methylation status | | 1.5 to 2.0 | Low-normal, monitoring appropriate | Dietary and lifestyle intervention first | | 2.0 to 4.0 | Preferred zone (premenopausal) | Maintain; retest in 6 to 12 months | | 4.0 to 6.0 | Acceptable; verify no I3C/DIM supplementation | Context-dependent | | >6.0 | Elevated; rule out supplement effect | Medication review |

Sex-Related Differences in Urinary Steroid Metabolites

Men and women excrete fundamentally different steroid metabolite profiles because of different gonadal steroid production rates. These differences are not subtle.

Women (Premenopausal)

Premenopausal women produce 100 to 400 micrograms of estradiol per day depending on cycle phase, with most of this appearing in urine as conjugated estrone, estriol, and their hydroxylated metabolites. Total urinary estrogen output (creatinine-corrected) peaks in the late follicular and luteal phases. Reference ranges for 2-OHE1 in women aged 18 to 50 on a standard clinical 24-hour urine test are approximately 3.0 to 18.0 micrograms/g creatinine, though the DUTCH (Dried Urine Test for Comprehensive Hormones) platform uses different units and population norms [7].

Men

Men produce approximately 35 to 50 micrograms of estradiol per day via aromatization of testosterone in peripheral tissues. Male 2-OHE1 excretion runs considerably lower than in premenopausal women, typically 1.0 to 6.0 micrograms/g creatinine on 24-hour collections. The 2-OH/16-OH ratio in men generally falls between 1.5 and 5.0, though normative data for men are less strong than for women, since most prospective breast-cancer studies enrolled women [8].

Testosterone metabolites dominate the male androgenic fraction. Testosterone glucuronide output in men is typically 30 to 130 micrograms/g creatinine, compared with 5 to 25 micrograms/g creatinine in women. Androsterone-to-etiocholanolone ratios can indicate 5-alpha-reductase activity, relevant when evaluating benign prostatic hyperplasia risk or response to finasteride.

Postmenopausal Women

After menopause, ovarian estrogen production drops more than 90%. Total urinary estrogen metabolite output falls sharply, and the relative contribution of 16-OHE1 often increases as a proportion of the smaller total pool, even though absolute 16-OHE1 output also falls. This shift partially explains why the 2-OH/16-OH ratio has less predictive power for breast-cancer risk in postmenopausal women in meta-analytic data [6]. The clinical implication is that postmenopausal ratio interpretation requires age-appropriate reference ranges, not premenopausal norms.

Cycle-Phase Variation in Urinary Estrogen Metabolites

Menstrual-cycle phase is one of the strongest sources of within-person variability in urinary estrogen metabolite output. Ignoring cycle phase when ordering or interpreting this test is a common clinical error.

Follicular Phase (Days 1 to 14)

Estrogen levels are rising but have not yet peaked. Urinary 2-OHE1 and 16-OHE1 are both in the lower portion of the reference range. The 2-OH/16-OH ratio in the early follicular phase may be artificially favorable because total estrogen throughput is low, not because the 2-OH pathway is particularly active.

Ovulation (Around Day 14)

The midcycle LH surge and estradiol peak produce the highest single-day estrogen metabolite output of the cycle. Both 2-OHE1 and 16-OHE1 rise, with the ratio relatively stable. A urine test collected on day 14 tends to reflect peak hydroxylation activity and may give the most clinically informative ratio.

Luteal Phase (Days 15 to 28)

Total urinary estrogen metabolites remain elevated. PDG rises sharply after ovulation, providing a marker of ovulation and adequate luteal function. The Endocrine Society notes that midluteal PDG values below 5 nanomoles per liter on dried-urine sampling suggest inadequate corpus luteum function [9]. Progesterone metabolites in this phase can partially modulate estrogen-receptor signaling, which is one rationale for using progesterone in HRT protocols aimed at breast-tissue protection.

Timing Recommendation

For premenopausal women, collection on days 19 to 22 of a standard 28-day cycle captures peak luteal output and gives the most reproducible 2-OH/16-OH ratio across repeat testing. The Precision Analytical DUTCH reference population uses day 19 to 22 samples for premenopausal normative data [7].

Normal and Optimal Ranges by Category

Reference ranges differ by collection method, lab platform, sex, age, and cycle phase. The table below summarizes the most commonly cited values.

| Analyte | Premenopausal Women (luteal) | Postmenopausal Women | Men | |---|---|---|---| | 2-OHE1 (mcg/g Cr) | 3.0 to 18.0 | 0.5 to 4.0 | 1.0 to 6.0 | | 16-OHE1 (mcg/g Cr) | 1.5 to 8.0 | 0.3 to 2.5 | 0.5 to 3.0 | | 2-OH/16-OH ratio | 1.0 to 7.8 (optimal 2.0 to 4.0) | 0.8 to 5.0 | 1.5 to 5.0 | | 4-OHE1 (mcg/g Cr) | 0.5 to 3.0 | 0.1 to 1.0 | 0.2 to 1.5 | | PDG (nM/mM Cr) | 5 to 35 (luteal) | <3.0 | N/A | | Testosterone glucuronide (mcg/g Cr) | 5 to 25 | 2 to 10 | 30 to 130 |

Sources: DUTCH normative database [7], published 24-hour urine reference intervals [8], and Endocrine Society biomarker position [9].

These ranges are not universal. Body mass index, dietary patterns, alcohol consumption, and genetic polymorphisms in CYP1A1, CYP1B1, and COMT all shift individual values. A woman with a CYP1B1 gain-of-function variant will tend to produce more 4-OHE1 regardless of lifestyle, which warrants targeted monitoring even when the 2-OH/16-OH ratio is acceptable [2].

Factors That Shift Urinary Metabolite Ratios

Diet

Cruciferous vegetables (broccoli, Brussels sprouts, cauliflower) contain indole-3-carbinol (I3C), which upregulates CYP1A1 and CYP1A2, increasing 2-hydroxylation. A controlled feeding study by Auborn et al. Found that daily consumption of 500 grams of cruciferous vegetables raised the 2-OH/16-OH ratio by a mean of 30% over four weeks [10]. Supplemental DIM (diindolylmethane), a stable I3C metabolite, produces similar effects at doses of 100 to 200 mg/day.

Body Composition

Adipose tissue is the primary site of aromatase activity and also preferentially produces 16-OHE1. Observational data show a negative correlation between BMI and the 2-OH/16-OH ratio; each 5-unit increase in BMI is associated with approximately a 0.3-point decrease in the ratio in premenopausal women [11]. Weight loss interventions that reduce fat mass correspondingly raise the ratio.

Methylation Status

COMT converts 2-OHE1 to the relatively inert 2-methoxyestrone. Low methyl-donor availability (folate deficiency, B12 deficiency, low SAM-e) reduces this conversion and may allow 2-OHE1 to be oxidized to reactive quinones. Evaluating the 2-OHE1 to 2-MeOE1 ratio provides a direct readout of COMT activity in vivo. A ratio above 3.0 for 2-OHE1/2-MeOE1 suggests inadequate methylation throughput and guides B-vitamin repletion [2].

Hormone Therapy

Oral estrogen substantially increases hepatic CYP1A2 activity, raising 2-hydroxylation and the 2-OH/16-OH ratio compared with transdermal estrogen, which bypasses first-pass hepatic metabolism. A crossover study by Lim et al. (N=32) found that oral estradiol 2 mg/day raised mean 2-OHE1 by 58% while transdermal estradiol 0.1 mg/day raised it by only 12% at 12 weeks [12]. This difference has implications for HRT formulation selection in women with low baseline 2-OH/16-OH ratios, though the clinical significance of the difference on long-term outcomes has not been established in randomized trial data.

How the DUTCH Test Measures These Metabolites

The Dried Urine Test for Comprehensive Hormones (DUTCH) collects four to five timed urine spots on filter paper over one day. Dried samples are stable at room temperature for up to 30 days, making collection practical. The platform uses liquid chromatography-tandem mass spectrometry (LC-MS/MS) for quantification, which avoids the cross-reactivity problems seen with older immunoassay-based urine panels [7].

The DUTCH reports metabolites as creatinine-corrected values (picograms or nanograms per milligram creatinine) and provides pattern interpretation relative to its own normative population. Clinicians should note that DUTCH reference ranges are not interchangeable with 24-hour urine reference ranges from clinical labs such as Quest or LabCorp, because collection timing and creatinine correction methods differ.

The American Association of Clinical Endocrinology (AACE) does not currently have a specific position statement on dried-urine steroid testing, but its 2022 comprehensive type 2 diabetes guidelines acknowledge LC-MS/MS as the preferred method for steroid quantification when high sensitivity and specificity are needed [13].

Clinical Applications: When to Order This Panel

Breast Cancer Risk Stratification

Women with a personal or family history of hormone-receptor-positive breast cancer, or with BRCA1/2 variants, may benefit from baseline and interval urinary metabolite testing to assess estrogen detox pathway efficiency. The ORDET data and Nurses' Health Study II data support using the 2-OH/16-OH ratio as one input into a broader risk assessment [4, 5].

Monitoring Hormone Replacement Therapy

Baseline testing before starting HRT and a repeat panel at 3 to 6 months allows clinicians to confirm that exogenous hormones are being metabolized through favorable pathways. The Endocrine Society's 2023 menopause hormone therapy clinical practice guideline states that "monitoring should include symptom assessment, adverse effects, and where clinically indicated, serum and urinary hormone metabolites to confirm appropriate metabolism" [9].

Evaluating Cycle Irregularities

PDG values in the luteal phase confirm ovulation and can detect luteal-phase defect, a common contributor to infertility and recurrent pregnancy loss. The American Society for Reproductive Medicine (ASRM) practice committee considers midluteal progesterone confirmation a standard part of ovulation verification [14].

Assessing Androgen Metabolism in Men

In men on testosterone replacement therapy (TRT), urinary androgen metabolites reveal how much testosterone is being converted to dihydrotestosterone (DHT) via 5-alpha-reductase (reflected in androsterone output) versus aromatized to estradiol. Men with high androsterone-to-testosterone-metabolite ratios may warrant consideration of 5-alpha-reductase monitoring, particularly if they have symptoms of benign prostatic hyperplasia.

Direct Clinician Perspective

Dr. Lara Briden, a naturopathic physician and author with expertise in period health, has written that "the urinary estrogen metabolite panel is one of the few tests that gives us a direct window into how a woman's body is handling estrogen, not just how much she's making" [15]. This view reflects a broader shift in functional and integrative endocrinology toward pathway assessment rather than isolated hormone-level snapshots.

The Endocrine Society's position on biomarkers for menopause states: "Urinary assays using mass spectrometry can provide a more complete picture of estrogen metabolism than serum estradiol alone, particularly in the context of hormone therapy management and cancer-risk assessment" [9].

Confounders and Test Limitations

Renal Function

Urinary metabolite concentrations depend partly on glomerular filtration rate. Creatinine correction normalizes for urine concentration but does not fully account for reduced renal clearance in chronic kidney disease (CKD stage 3 or higher). In patients with estimated GFR below 45 mL/min/1.73m², serum steroid metabolite testing or 24-hour urine with measured creatinine clearance is preferable.

Medication Interactions

• Proton pump inhibitors (PPIs) reduce gastric acid and may affect enterohepatic estrogen recirculation.
• Broad-spectrum antibiotics disrupt gut microbiome beta-glucuronidase activity, reducing estrogen deconjugation and enterohepatic recirculation, which can transiently lower urinary estrogen metabolite output by 20 to 40%.
• Tamoxifen and aromatase inhibitors dramatically suppress estrogen metabolite output; testing during these therapies requires therapy-specific reference ranges.

Dietary Protein

Creatinine excretion correlates with muscle mass. In individuals with low muscle mass or very low protein intake, creatinine-corrected values may be falsely elevated. Timed 24-hour collections with measured creatinine output mitigate this problem.